



US005510379A

United States Patent [19][11] **Patent Number:** **5,510,379**

Lee et al.


[45] **Date of Patent:** **Apr. 23, 1996**[54] **SULFONATE ACAT INHIBITORS**[58] **Field of Search** 558/49, 50; 514/517,
514/510[75] **Inventors:** **Helen T. Lee**, Ann Arbor; **Joseph A. Picard**, Canton; **Drago R. Sliskovic**, Ypsilanti, all of Mich.[56] **References Cited**[73] **Assignee:** **Warner-Lambert Company**, Morris Plains, N.J.

U.S. PATENT DOCUMENTS

4,567,004 1/1986 Blank et al. 260/465 R

[21] **Appl. No.:** **359,144**[22] **Filed:** **Dec. 19, 1994**[51] **Int. Cl.⁶** **C07C 309/69**; C07C 309/70;
A61K 31/095; C07D 487/04*Primary Examiner*—Cecilia Tsang
Assistant Examiner—King Lit Wong
Attorney, Agent, or Firm—Charles W. Ashbrook; Todd M. Crissey[52] **U.S. Cl.** **514/517**; 514/510; 514/513;
514/300; 514/404; 514/312; 514/457; 514/341;
514/256; 514/252; 514/314; 514/246; 514/248;
514/259; 514/274; 514/351; 514/387; 514/445;
514/443; 514/473; 514/470; 514/469; 514/247;
514/255; 514/424; 514/407; 514/372; 514/365;
514/376; 514/380; 514/384; 514/359; 514/392;
514/386; 514/367; 514/418; 514/415; 514/311;
514/309; 514/307; 558/50; 558/49; 558/52;
546/122; 546/153; 546/294; 546/157; 546/172;
546/141; 546/147; 546/146; 548/370.1;
548/370.4; 548/550; 548/551; 548/213;
548/187; 548/228; 548/229; 548/243; 548/255;
548/264.4; 548/324.1; 548/166; 548/178;
548/180; 548/251; 548/486; 548/484; 548/510;
548/265.4; 549/471; 549/399; 549/410;
549/65; 549/66; 549/52; 549/51; 549/479;
549/466; 544/215; 544/237; 544/235; 544/283;
544/315; 544/319; 544/298; 544/239; 544/408[57] **ABSTRACT**

β-Carboxy sulfonates of the formula



wherein R₁ is aryl, R₃ and R₄ are hydrogen or alkyl, Y is -O-, -S-, or -NR₂-, and R₅ is alkyl or aryl are potent inhibitors of the enzyme acyl CoA:cholesterol acyltransferase (ACAT) and are thus useful for treating hypercholesterolemia and atherosclerosis.

13 Claims, No Drawings

SULFONATE ACAT INHIBITORS

BACKGROUND OF THE INVENTION

This invention provides new chemical compounds characterized as being β -carboxy sulfonates. The compounds inhibit acyl-CoA: cholesterol acyltransferase (ACAT), the enzyme responsible for the esterification of dietary cholesterol. Such agents thus decrease the absorption of dietary cholesterol and therefore provide a therapy for individuals with hypercholesterolemia and atherosclerosis.


High levels of cholesterol have been associated with heightened risk for development of several disease states, most notably coronary heart disease. A great deal of effort has been devoted to finding ways to lower cholesterol levels in biological systems. The approach of lowering cholesterol intake by modifying diet has met with only limited success. The ACAT enzyme is known to catalyze the esterification of dietary cholesterol, and has been implicated in several aspects of the atherosclerotic process in animals. One approach to lowering cholesterol then is to inhibit the ACAT enzyme. While several ACAT inhibitors have been identified (see for example EP 0570245), the need continues to identify and develop new ACAT inhibitors having improved therapeutic properties.

An object of this invention is therefore to provide a new series of compounds which are β -carboxy sulfonate derivatives and which have demonstrated excellent ACAT inhibitory properties. Another object is to provide pharmaceutical formulations comprising the sulfonates and a carrier or excipient, and a method for inhibiting the ACAT enzyme by administering a compound of the invention.

SUMMARY OF THE INVENTION

This invention concerns new compounds which are β -carboxy sulfonates and which inhibit the ACAT enzyme.

The compounds of the invention have the Formula I



wherein R_1 is selected from

(a) phenyl which is unsubstituted or is substituted with from 1 to 3 substituents selected from

C_1 - C_4 alkyl,
 C_1 - C_4 alkoxy,
 C_1 - C_4 alkyl thio,
 hydroxy,
 halo,
 nitro,
 cyano,
 trifluoromethyl,
 -COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and which is straight or branched,

$-(\text{CH}_2)_m\text{NR}_x\text{R}_y$, wherein m is 0 or 1, and each of R_x and R_y is independently hydrogen or C_1 - C_4 alkyl;

(b) 1- or 2-naphthyl which is unsubstituted or substituted with from 1 to 3 substituents selected from

C_1 - C_4 alkyl,
 C_1 - C_4 alkoxy,
 C_1 - C_4 alkylthio,

hydroxy,
 halo,
 nitro,

cyano,


trifluoromethyl,

-COOH,


-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and which is straight or branched,

$-(\text{CH}_2)_m\text{NR}_x\text{R}_y$, wherein m is 0 or 1, and each of R_x and R_y is independently hydrogen or C_1 - C_4 alkyl;

(c) the group



(d) the group



wherein R_8 and R_9 independently are C_1 - C_4 alkyl or phenyl, and R_{10} is a straight or branched hydrocarbon group having from 1 to 18 carbon atoms which is saturated or is unsaturated containing one double bond or two nonadjacent double bonds; phenyl; phenyl substituted with from 1 to 3 substituents selected from

C_1 - C_4 alkyl,

C_1 - C_4 alkoxy,

hydroxy,

halo,

nitro,

cyano,

trifluoromethyl,


-COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight or branched,

$-(\text{CH}_2)_m\text{NR}_x\text{R}_y$, wherein m , R_x , and R_y are as defined above; or

a heterocyclic group selected from 2-, 3-, or 4-pyridyl, 2-, 4-, or 5-pyrimidinyl, 2-, or 3-pyrazinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 3- or 4-pyridazinyl, and the N-oxides thereof;

(e) the group




(f) a straight or branched hydrocarbon group having from 1 to 18 carbon atoms which is saturated or is unsaturated

3

containing one double bond or two nonadjacent double bonds;

(g) a cycloalkyl group having from 3 to 10 carbon atoms;

(h) the group





wherein — denotes a single or double bond; Q and Z are each independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, or halo;


W is oxygen or two hydrogen atoms;

R¹¹ is hydrogen or C₁-C₄ alkyl, and n' is 0 or 1;

(i) is selected from the group



and



wherein R¹², R¹³, R¹⁴, and R¹⁵ are each independently hydrogen,

halo,

C₁-C₄ alkyl,

C₁-C₄ alkoxy,

C₁-C₄ alkylthio,

cycloalkylthio of 5 to 7 carbon atoms,

phenylalkylthio in which alkyl is 1 to 4 carbon atoms,

substituted phenylthio, heteroarylthio, or heteroaryloxy;

and B, D, E, and G are nitrogen or carbon where one or more of B, D, and E is nitrogen; with the proviso that when G = N, the group is attached to the nitrogen atom of Formula I at the four or five position of the pyrimidine ring (a and b); or

(j) a 5- or 6-membered monocyclic or fused bicyclic heterocycle containing from 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; R₃ and R₄ independently are C₃-C₆ cycloalkyl, hydroxy-C₁-C₄ alkyl, C₁-C₄ alkoxy, hydrogen, C₁-C₄ alkyl, phenyl, 1- or 2-naphthyl, or phenyl or naphthyl substituted with from 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, nitro, cyano, trifluoromethyl, phenyl, or C₃-C₆ cycloalkyl

4

or R₃ and R₄ taken together with the carbon to which they are attached complete a C₃-C₈ carbocyclic ring;

Y is -O-, -S-, or -NR₂-, wherein R₂ is hydrogen, C₁-C₄ alkyl, phenyl, C₁-C₄ alkyl, phenyl, wherein the phenyl may be substituted with 1, 2, or 3 groups selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, hydroxy, halo, nitro, cyano, trifluoromethyl, and COOH;

R₅ is R₆, C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl and alkyl, alkenyl and alkenyl substituted with one or two groups defined by R₆, where R₆ is hydrogen, C₃-C₆ cycloalkyl, phenyl, 1- or 2-naphthyl, and phenyl and naphthyl substituted with from 1 to 3 substituents selected from:

C₁-C₄ alkyl,

C₁-C₄ alkoxy,

C₁-C₄ alkylthio,

phenyl,

hydroxy,

halo,

nitro,

cyano,

trifluoromethyl,


-COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and which is straight or branched,

-(CH₂)_mNR_xR_y, wherein m is 0 or 1, and each of R_x and R_y is hydrogen or a straight chain alkyl group having 1 to 4 carbon atoms; and

R₆ is heteroaryl selected from a 5- or 6-membered monocyclic or fused bicyclic heterocyclic group containing at least 1 to 4 heteroatoms in at least one ring, said heteroatoms being nitrogen, oxygen, or sulfur and combinations thereof, said heterocyclic group being unsubstituted or substituted with amino, halo, nitro, hydroxy, cyano, trifluoromethyl, or an alkyl group having from 1 to 20 carbon atoms and the N-oxides thereof.

Preferred compounds of the invention have the Formula II



wherein R₁, Y, and R₅ are as defined above. Further preferred are those of the above formula in which Y is -O-, -S-, or -NH-, and especially where Y is -NH-. Additionally preferred are compounds of Formula II wherein R₁ is phenyl or substituted phenyl, Y is -O- or S, and R₅ is C₆-C₂₀ alkyl, phenyl, or substituted phenyl. Preferred substituted phenyl groups are di- and trialkyl, such as diisopropyl and triisopropyl.

Particularly preferred compounds have Formula II wherein:

A. R₁ is phenyl or phenyl substituted with 1 or 2 C₁-C₄ alkyl groups;

A(1) Y is NH and R₅ is C₆-C₂₀ alkyl;

A(2) Y is NH and R₅ is phenyl or phenyl substituted with 1 or 2 C₁-C₄ alkyl or C₁-C₄ alkoxy groups;

A(3) Y is NH and R₅ is pyridyl or pyridyl substituted with 1 or 2 C₁-C₄ alkyl groups;

A(4) Y is S and R₅ is C₆-C₂₀ alkyl;

A(5) Y is O and R₅ is C₆-C₂₀ alkyl;

A(6) Y is O and R₅ is phenyl or phenyl substituted with 1 or 2 C₁-C₄ alkyl groups;

A(7) Y is NH and R₅ is tetrazolyl or tetrazolyl substituted with a C₆-C₂₀ alkyl group;

B. R₁ is phenyl substituted with 1, 2, or 3 C₁-C₄ alkoxy groups;

B(1) Y is NH and R₅ is phenyl or phenyl substituted with 1, 2, or 3 C₁-C₄ alkoxy groups;

B(2) Y is NH and R₅ is C₆-C₂₀ alkyl;

B(3) Y is S and R₅ is C₆-C₂₀ alkyl;

B(4) Y is O and R₅ is C₆-C₂₀ alkyl;

B(5) Y is O and R₅ is phenyl or phenyl substituted with 1, 2, or 3 C₁-C₄ alkoxy groups;

C. R₁ is 1- or 2-naphthyl or 1- or 2-naphthyl substituted with 1, 2, or 3 groups selected from C₁-C₄ alkyl or C₁-C₄ alkoxy;

C(1) Y is NH and R₅ is C₆-C₂₀ alkyl, phenyl, or phenyl substituted with 1, 2, or 3 groups selected from C₁-C₄ alkyl or C₁-C₄ alkoxy;

C(2) Y is S and R₅ is C₆-C₂₀ alkyl;

C(3) Y is O and R₅ is C₆-C₂₀ alkyl, phenyl, tetrazolyl, or phenyl substituted with 1, 2, or 3 C₁-C₄ alkyl groups;

C(4) Y is O and R₅ is hydrogen;

D. R₁ is C₁-C₂₀ alkyl;

D(1) Y is O and R₅ is phenyl or phenyl substituted with 1 or 2 C₁-C₄ alkyl groups;

D(2) Y is S and R₅ C₆-C₂₀ alkyl;

E. R₁ is pyridyl or pyridyl substituted with 1 or 2 C₁-C₄ alkyl groups;

E(1) Y is O or S and R₅ C₆-C₂₀ alkyl;

F. R₁ is 4,6-dialkylpyridin-5-yl;

F(1) Y is NH and R₅ C₆-C₂₀ alkyl;

F(2) Y is S and R₅ is phenyl or phenyl substituted with 1, 2, or 3 C₁-C₄ alkyl groups;

G. R₁ is 4-(2-chlorophenyl)-5,7-dimethylquinolin-2-yl;

G(1) Y is O and R₅ is C₆-C₂₀ alkyl;

G(2) Y is NH and R₅ is phenyl or phenyl substituted with 1, 2, or 3 C₁-C₄ alkoxy groups;


G(3) Y is S and R₅ is C₂-C₂₀ alkenyl;

The most preferred compounds of the invention are defined by Formula II when R₁ is phenyl or substituted phenyl, Y is -NH- and R₅ is phenyl or dialkylphenyl.

Also provided by this invention are pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable excipient, carrier, or diluent. Preferred formulations are those having a compound of Formula II or any of the preferred compounds of A-G as the active ingredient. The invention also provides a method of treating hypercholesterolemia, atherosclerosis, and inhibiting the ACAT enzyme, comprising administering to a subject an effective amount of a compound of Formula I to treat such conditions and to inhibit such enzyme.

DETAILED DESCRIPTION

The compounds of this invention are named as sulfonates, and more specifically as carbonylmethyl sulfonates. For example, the invention compound of the formula



will be named phenyl methoxycarbonylmethyl sulfonate.

Pharmaceutically acceptable salts of the compounds of Formula I are also included as a part of the present invention. Suitable acids for forming salts of the compounds of Formula I containing a basic group such as amino or pyridyl include, but are not necessarily limited to acetic, benzoic, benzenesulfonic, hydrobromic, hydrochloric, citric, fumaric, gluconic, glucuronic, glutamic, lactic, malic, maleic, methanesulfonic, pamoic, salicylic, stearic, succinic, sulfuric, and tartaric acids. Additional acids for use to form acid salts of the compounds of Formula I include, but are not necessarily limited to, those acids found in Tables 3 and 4 of Grant & Hackh's Chemical Dictionary, Fifth Edition, 1987:11-13. The acid addition salts are formed by procedures well known in the art.

Certain compounds of the present invention may also exist in different isomeric forms, specifically stereoisomeric forms, by virtue of the presence of asymmetric centers in the compound. The present invention contemplates all stereoisomers that may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers by chiral chromatographic columns.

Further, the compounds of this invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

In Formula I, R₅ can be C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, or C₂-C₂₀ alkynyl. Each of these groups can have one or two groups defined by R₆ attached, for example a substituted or unsubstituted phenyl, or a substituted or unsubstituted naphthyl, or a cycloalkyl such as cyclopropyl can be attached to the carbon chain. Illustrative examples of straight or branched saturated hydrocarbon chains having from 1 to 20 carbon atoms include methyl, ethyl, 2-cyclobutyl-2-phenylethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, 5-phenylpentyl, 2-cyclopropyl-5-phenylpentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-undecyl, n-dodecyl, n-hexadecyl, 2,2-dimethyldodecyl, 2-tetradecyl, and n-octadecyl groups.

Illustrative examples of straight or branched hydrocarbon alkenyl chains having from 2 to 20 carbon atoms and having one double bond or two nonadjacent double bonds include ethenyl, 2-propenyl, 2-butenyl, 4-cyclobutyl-2-butenyl, 3-pentenyl, 2-octenyl, 5-nonenyl, 4-undecenyl, 5-heptadecenyl, 3-octadecenyl, 9-octadecenyl, 9-phenyl-9-octadecenyl, 2,2-dimethyl-11-eicosenyl, 9,12-octadecadienyl, and hexadecenyl. Typical alkynyl groups are those having from 2 to 20 carbon atoms with one triple bond or two monoadjacent triple bonds and include 2-octynyl, 5-hepta-3-decynyl, and 4-phenyl-2-butylyl.

R₁ in Formula I includes phenyl substituted with 1, 2, or 3 groups such as C₁-C₄ alkyl, C₁-C₄ alkoxy and C₁-C₄ alkylthio. Straight or branched C₁-C₄ alkyl groups include methyl and isopropyl. Straight or branched alkoxy groups having 1 to 4 carbon atoms include methoxy, ethoxy, n-propoxy, n-butoxy, and isopropoxy. C₁-C₄ alkylthio includes groups such as methylthio, ethylthio, isopropylthio, and the like.

Cycloalkyl groups having from 3 to 10 carbon atoms which R₁ and R₄ may represent include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

Halo is fluoro, chloro, bromo, or iodo, but preferably bromo and chloro.


A 5- or 6-membered monocyclic or fused bicyclic heterocycle is a monocyclic or fused bicyclic aromatic ring containing at least one to four heteroatoms in at least one

7

ring, such as nitrogen, oxygen, or sulfur, or a combination thereof. Such a heterocyclic group includes, for example, thienyl, benzothienyl, furanyl, benzofuranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, pyrazolyl, isothiazolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, benzothiazolyl, indolyl, quinolinyl, isoquinolinyl, or N-oxides of heterocycles containing a nitrogen atom.


More specifically, such a heterocycle may be a 2- or 3-thienyl; 2- or 3-furanyl; 2-, 3-, or 4-pyridyl or 2-, 3-, or 4-pyridinyl-N-oxide; 2-, 4-, or 5-pyrimidinyl; 3- or 4-pyridazinyl; 2-pyrazinyl; 2-pyrazinyl-N-oxide; 2- or 3-pyrrolyl; 3-, 4-, or 5-pyrazolyl; 2-, 4-, or 5-thiazolyl; 3-, 4-, or 5-isoxazolyl; 2-, 4-, or 5-oxazolyl; 3-, 4-, or 5-isothiazolyl; 5-tetrazolyl; 3- or 5-(1,2,4)-triazolyl; 4- or 5-(1,2,3)-triazolyl; 2-, 4-, or 5-imidazolyl; 2-, 3-, 4-, 5-, 6-, or 7-indolyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl; 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl; 2-, 4-, 5-, 6-, or 7-benzothiazolyl; or 2-, 3-, 4-, 5-, 6-, or 7-benzothienyl.

A preferred embodiment of this invention includes compounds having the formula




where Y is O, S, or NH, and especially NH.

Also preferred are compounds of the formula




where Y is O, S, or NH, and especially NH.

Another class of compounds provided by the invention have the formula




Another class of invention compounds have the formula




where Y is O, S, or NH, and substituted phenyl is phenyl having 1, 2, or 3 substituents as defined above

8

Another preferred group of compounds of the invention have the formula




Still other compounds of the invention have the formula




wherein R₂, R₃, R₄, R₁₁, W, n', Q, and Z are as defined above, and Y is O, S, or NH.

The compounds of this invention are prepared by any of several synthetic routes utilizing routine methodology well known to those skilled in the art of organic chemistry. The compounds are prepared from readily available starting materials and reactants.

In a preferred embodiment, compounds of Formula II



are prepared by reacting an alcohol, thiol, or amine of the formula H-Y-R₅ with a sulfonic acetyl halide of the formula



where R₁ is as defined above and halo is preferably bromo or chloro. The sulfonic acetyl halides are readily prepared by starting with a sulfonic acetic acid, which can be reacted with an alcohol to give the corresponding sulfonic acetic acid ester, which reacts with a halogenating agent to give the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.